Model-based projections of the population-level impact of hepatitis A vaccination in Mexico
| العنوان: | Model-based projections of the population-level impact of hepatitis A vaccination in Mexico |
|---|---|
| المؤلفون: | Rodrigo DeAntonio, Luis Romano-Mazzotti, Adrian Cassidy, Thierry Van Effelterre, Cinzia Marano |
| المصدر: | Human Vaccines & Immunotherapeutics. 8:1099-1108 |
| بيانات النشر: | Informa UK Limited, 2012. |
| سنة النشر: | 2012 |
| مصطلحات موضوعية: | Adult, Male, medicine.medical_specialty, Adolescent, Population level, viruses, Immunology, Hepatitis A vaccine, Young Adult, Humans, Immunology and Allergy, Medicine, Young adult, Child, Mexico, Pharmacology, Hepatitis A Vaccines, Models, Statistical, business.industry, Incidence, Incidence (epidemiology), Public health, Vaccination, Infant, Hepatitis A, medicine.disease, Virology, Child, Preschool, Female, Hepatitis A vaccination, business, Research Paper, Demography |
| الوصف: | There are indications of a shift in the pattern of hepatitis A (HAV) in Mexico from high to intermediate endemicity, progressively increasing the mean age of infection and the proportion of cases which are symptomatic. This study estimated the potential impact of universal infant HAV vaccination in Mexico with two doses of Havrix™ at 12 and 18 mo of age on all HAV infections and symptomatic HAV infections. We developed a dynamic transmission model that accounts for changes in demography and HAV epidemiology. It was calibrated using Mexican age-specific seroprevalence and symptomatic HAV incidence data. With 70% first-dose coverage and 85% second-dose coverage, the calibrated model projected that HAV vaccination would reduce the incidence of all HAV infections (symptomatic and asymptomatic) after the first 25 y of vaccination by 71-76% (minimum and maximum for different transmission scenarios). The projected reduction in cumulative incidence of symptomatic HAV infections over the first 25 y of vaccination was 45-51%. With 90% first-dose coverage and 85% second-dose coverage, the projected reduction in incidence of all HAV infections was 85-93%, and the projected reduction in the cumulative incidence of symptomatic HAV infections was 61-67%, over a 25-y time frame. Sensitivity analyses indicated that second-dose coverage is important under the conservative base-case assumptions made about the duration of vaccine protection. The model indicated that universal infant HAV vaccination could substantially reduce the burden of HAV disease in Mexico. |
| تدمد: | 2164-554X 2164-5515 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54c924d0e5b0cc1921f0c64b95b885b4 https://doi.org/10.4161/hv.20549 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....54c924d0e5b0cc1921f0c64b95b885b4 |
| قاعدة البيانات: | OpenAIRE |
PDF full text from Publisher | تدمد: | 2164554X 21645515 |
|---|